PG545

 
Brisbane, Australia, 20th September 2011-Progen Pharmaceuticals Ltd (ASX:PGL, OTC:PGLA) announced today that the current Phase 1a PG545 human clinical trial in advanced cancer patients has been put on hold due to unexpected local injection site reactions seen in patients.
 
 
These reactions appear to be a very specific side effect in humans and were not seen to this extent in the extensive preclinical animal testing of the drug.